Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Annex Advisory Services LLC

Annex Advisory Services LLC increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 18.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 87,145 shares of the company’s stock after acquiring an additional 13,710 shares during the period. Medpace makes up about 0.9% of Annex Advisory Services LLC’s holdings, making the stock its 25th largest holding. Annex Advisory Services LLC’s holdings in Medpace were worth $28,952,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Centaurus Financial Inc. raised its position in Medpace by 2.0% in the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after purchasing an additional 29 shares in the last quarter. Lindenwold Advisors INC raised its holdings in Medpace by 1.6% in the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock valued at $676,000 after acquiring an additional 32 shares in the last quarter. M&T Bank Corp lifted its stake in Medpace by 1.2% in the third quarter. M&T Bank Corp now owns 3,199 shares of the company’s stock worth $1,068,000 after acquiring an additional 37 shares during the last quarter. Nations Financial Group Inc. IA ADV grew its holdings in Medpace by 1.7% during the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 2,376 shares of the company’s stock worth $793,000 after acquiring an additional 39 shares in the last quarter. Finally, Integrated Investment Consultants LLC increased its position in shares of Medpace by 6.0% in the 4th quarter. Integrated Investment Consultants LLC now owns 692 shares of the company’s stock valued at $230,000 after purchasing an additional 39 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Trading Up 0.2 %

MEDP stock opened at $337.35 on Monday. The company has a market capitalization of $10.48 billion, a P/E ratio of 29.54, a PEG ratio of 1.80 and a beta of 1.36. The business has a 50 day simple moving average of $340.52 and a 200-day simple moving average of $356.98. Medpace Holdings, Inc. has a twelve month low of $284.32 and a twelve month high of $459.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. The firm had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. Medpace’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.22 EPS. Research analysts predict that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on MEDP. Truist Financial decreased their price objective on shares of Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Redburn Atlantic initiated coverage on Medpace in a research report on Monday, October 14th. They set a “buy” rating and a $404.00 price objective for the company. Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. UBS Group downgraded Medpace from a “buy” rating to a “neutral” rating and lowered their price target for the company from $420.00 to $350.00 in a report on Friday, September 27th. Finally, William Blair reissued an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $380.56.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.